Head to head
Celestica vs Amphenol
Side-by-side on the measures that matter, with a plain-English read. Full detail: CLS · APH
CLS
Celestica
201.80-16.00%
1-year price shape — -29% over the period
Quant Rating E · 11/100
vs
APH
Amphenol
69.72-7.79%
1-year price shape — +8% over the period
Quant Rating D · 43/100
1-year performance, rebased to 100
Amphenol edges it on the scoreable measures. Amphenol has the highest Quant Rating (43); Amphenol has done best over the past year (+8%); Amphenol pays the highest dividend yield.
| CLS | APH | |
|---|---|---|
| Snapshot | ||
| Sector | -- | Electronic Components |
| Last price | 201.80 | 69.72 |
| Change today | -16.00% | -7.79% |
| 1-year return | -28.5% | +7.5% |
| Market cap | $25.45B | $172.16B |
| 52-week range | 197.50 – 474.03 | 58.82 – 89.93 |
| Valuation | ||
| P/E (TTM) | 19.04 | 30.31 |
| P/E percentile, own 5-yr range | 50th | 44th |
| P/B | 4.10 | 10.05 |
| Dividend yield | 0.00% | 0.72% |
| Profitability & growth | ||
| EPS (TTM) | 7.16 | 1.67 |
| Net profit (TTM) | $902.96M | $4.12B |
| Revenue (TTM) | $18.23B | $33.05B |
| Provider revenue period date | 2026-09-29 | 2026-09-29 |
| Revenue growth (YoY) | +82.5% | +65.1% |
| Gross margin | 11.5% | 38.8% |
| Operating margin | 8.3% | 28.3% |
| Net margin | 6.8% | 18.0% |
| Free cash flow (TTM) | $545.40M | $5.12B |
| Provider cash-flow period date | 2026-09-29 | 2026-09-29 |
| Ownership & sentiment | ||
| Institutional ownership | 74.3% | 96.2% |
| Insider activity (12mo) | 31 buy / 17 sell | 24 buy / 25 sell |
| Short interest (% of float) | 3.7% | 1.1% |
| Analyst consensus | 100% buy (15) | 91% buy / 9% hold (11) |
| Analyst price target | $450 (+123%) | $109 (+56%) |
| StockVane view | ||
| StockVane Quant Rating | E (11) | D (43) |
| Company | ||
| Employees | 29,591 | 170,000 |
| Founded | 1994 | 1932 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.